Merck KGaA hikes 2026 EBITDA target to 6.4 billion euros
Global Banking & Finance Review · · AI-summarised by FinFlash
Germany's Merck KGaA raised its full-year outlook for the third time, now targeting adjusted EBITDA of 6.2 to 6.4 billion euros, up from 5.9 to 6.3 billion, and revenue of 21.5 to 21.9 billion euros. Third-quarter net revenue rose 5.8% to 5.6 billion euros, while EBITDA edged up 0.8% to 1.7 billion. The group agreed in June to buy Bio-Techne for The upgrade supports Merck KGaA shares and European healthcare and life-science tools names; watch margin commentary on the Bio-Techne integration. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context